Melek Kanarya Vardar1, Mehmet Emin Ceylan1, Bariş Önen Ünsalver1. 1. Melek Kanarya Vardar, MD, Psychiatrist. Baǧcilar Education and Research Hospital Psychiatry Department. Mehmet Emin Ceylan, MD, PHD, Professor of Psychiatry. Üsküdar University, Faculty of Humanities and Social Sciences, Department of Philosophy. Bariş Önen Ünsalver, MD, Assistant Professor of Psychiatry Üsküdar University, Faculty of Humanities and Social Sciences, Department of Psychology.
Abstract
Objective: Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD). Methods: 80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records. Results: There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction. Conclusion: Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.
Objective: Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD). Methods: 80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records. Results: There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction. Conclusion: Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.
Authors: Lucia Ricciardi; Tamara Pringsheim; Thomas R E Barnes; Davide Martino; David Gardner; Gary Remington; Donald Addington; Francesca Morgante; Norman Poole; Alan Carson; Mark Edwards Journal: Can J Psychiatry Date: 2019-02-21 Impact factor: 4.356